All patients admitted to the coronary care unit with suspected acute coronary syndromes were evaluated by serial electrocardiography and blood draws on admission and at 4 and 12 h from admission. Diagnosis was based on conventional WHO criteria. Samples were measured for creatine kinase (CK), cardiac troponin T (cTn'T), myoglobin. CK isoenzyme MB (CK-MB) and cardiac troponin I (cTnI). A set of samples from individuals undergoing extreme endurance training was also examined. Analytical imprecision was consistent with published quality goals. Samples were stable for cTnI under a range of storage conditions, including multiple freeze-thaw cycles. CK-MB, cTnI and cTnT were equally efficient for the diagnosis of acute myocardial infarction. irrespective of the final diagnostic criteria used. Both cTnI and cTnT were of equal efficiency in the identification of a high-risk subgroup of patients with unstable angina. Significant elevations of cTnI were not seen in an endurance-training group.
INTRODUCTION
The conventional diagnostic tests for acute myocardial infarction (AMI) include the measurement of creatine kinase (CK) and its MB isoenzyme (CK-MB). CK-MB measurement is clinically and analytically superior to other testsl" and CK-MB mass the method of choice.r" Despite this, measurement of CK-MB is not in routine use as the first-line test in all diagnostic laboratories, especially in the United Kingdom. A criticism in the designation of CK-MB mass as the 'gold standard' against which all other tests are evaluated is that classification becomes circular. AM I is diagnosed with CK-MB mass; this makes CK-MB mass measurement by definition 100% sensitive and specific. The development of techniques for measuring cardiac structural proteins such as cardiac troponin T (cTnT) and cardiac troponin I (cTnI) provides the laboratory with a marker that is completely specific for cardiac damage.P' Clinical studies have shown that cardiac troponin measurement can be related to outcome, which is important in an era of cost containment and evidence-based medicine." 16 The ability, with new laboratory methods, to detect myocardial damage which is prognostically significant, means that it is necessary to reconsider current diagnostic criteria. The measurement of cardiac troponin can reveal the presence of unsuspected myocardial damage but causes problems with test evaluation. as the diagnostic 'gold standard' of CK-MB mass is no longer appropriate. This has led to an apparent lack of specificity when reporting the diagnostic performance of cardiac troponin measurement." The situation is further complicated as there is a range of methods currently available for cTnl measurement, but agreement between them is variable." The lack of standardization of cTnl methods between manufacturers and the problems of different epitope recognition 19 and epitope stability2o.2\ has caused clinical confusion. In view of this, it is necessary to evaluate methods for cTnl individually. We have evaluated a new method for cTnI and other cardiac markers by considering diagnostic efficiency against independent diagnostic criteria and using outcome measures. The populations studied comprised an unselected cardiac population representing routine clinical practice and a non-cardiac population undergoing endurance training.
PATIENTS AND METHODS

Study population
Two populations were studied, one with a high prior probability of ischaemic myocardial damage (the cardiac population), and the second an extreme low-probability group with elevation of conventional cardiac enzymes but no expected myocardial damage (the non-cardiac population). The study was performed in accordance with the requirements of the local research ethics committee.
The cardiac population comprised all sequential admissions to a UK district general hospital coronary care unit (CCU) with a diagnosis of suspected acute coronary syndrome (ACS). Blood samples were drawn according to the routine sampling protocol on admission, and at 4 and 12h from admission. Samples were taken into Vacutainer tubes (SST, Becton Dickinson, Oxford, UK), dispatched immediately to the laboratory, allowed to clot and centrifuged. An aliquot of serum was immediately separated and frozen at -70°C. This was subsequently thawed (a maximum of 6 months after collection, range 1 week to 6 months, median 5 weeks) and assayed for cTnI, myoglobin and CK-MB mass. The remaining sample was assayed immediately for CK (admission and 4-h samples) or CK and cTnT (l2-h samples), according to the routine clinical cardiac investigation protocol. All patients were investigated, diagnosed and managed by the physicians and cardiologists according to the standard chest pain management protocol, using the ECG (electrocardiogram) plus CK and cTnT as cardiac markers. A total of 279 patients were studied, 189 male and 90 female, age range 274-87'9 years, median 65,3, lower quartile (LQ) 57,4, upper quartile (UQ) 73·7. Total reported duration of symptoms ranged from none to 33 days, median 6·5 h, LQ 2·7, UQ 19'7. The most recent episode of cardiac symptoms ranged from 0 to 129h. median 3 h, LQ 1,5, UQ 6·5. A subset of the total dataset comprising all those with symptoms of less than 12h duration was also studied. This comprised 165 males and 72 females, age range 27·4-87·9 years, median 65,0, LQ 57·4, UQ 73·5. The duration of symptoms ranged from 0 to 12h, median 2'7h, LQ 1,0, UQ 4·3. The non-cardiac population consisted of Royal Marines undergoing commando training. All were physically fit individuals who had had a full medical examination before selection. The commando training course is an extreme physical endurance test and results in substantial elevation of CK and CK-MB values of definite musculoskeletal origin in a population with no evidence of ischaemic heart disease. Blood was taken during training at I, 12, 19, 24 and 29 weeks into non-gel plain Vacutainers, allowed to clot, centrifuged, and the serum separated. Samples were frozen at -20°C initially, and then transferred to -70°C for longer-term storage. Samples were assayed for CK within I month of collection, and subsequently analysed after long-term storage (5 years) for cTnT and cTnI. Previous studies by us (unpublished data) had found that cTnT (Roche) and cTnI (Opus plus, AxSYM) are not affected by multiple freeze-thaw cycles and are stable in long-term storage (for at least 3 years). This stability of cTnl (as measured on the AxSYM Analyser, Abbott Diagnostics) has been confirmed by other workers.F The training cohort comprised 219 men, age range 18-26 years, median 20·8 years; 88 samples were analysed from week 24 in training, the point of maximum physical exertion.
Analytical methods Creatine kinase was measured using an Axon analyser (Bayer Diagnostics, Newbury, Essex, UK). Inter-assay CVs were 2·9% at 179·5U/L and 2·2% at 671·3 U/L. The upper reference interval for the laboratory was 200 U/L. Measurement of cTnl, CK-MB and myoglobin was performed on the ACS:180 (Bayer Diagnostics, Newbury, Essex, UK) according to the manufacturer's recommended methods. All three assays are two-site immunometric assays. Assay characteristics and performance data given below are as supplied by the manufacturer. Total assay CVs are~5'5% in the range 2,49-46·53 J-Ig/L; assay range up to 50 J-Ig/L. The total assay CV is~20% at 0·1 /lg/L (Bayer Diagnostics, personal communication) with an assay minimum detectable concentration (MDC, defined as the relative light units that are 2 SD above the relative light units obtained from 20 replicates of the zero standard) of < 0·1 /lg/L. Total assay CVs for CK·MB are~3·5% in the range 3·77-197·84j.lg/L. The assay range is up to 300mg/L with an MDC 0·18j.lg/L. Total assay CVs for myoglobin are~5'3% in the range 57·7-648·8 j.lg/L. The assay range is up to 1000j.lg/L, with MDC 3/lg/L.
Cardiac troponin T was measured by an electrochemical luminescence immunoassay using an Elecsys 1010 (Roche Diagnostics, Lewes, UK) according to the manufacturer's recommended method. This assay uses the same antibodies as the second-generation Enzymun and is calibrated against a bovine cTnT standard. The inter-assay CVs quoted by the manufacturer were 5·5% at 0'32/lg/L and 5·4% at 6·0/lg/L. Data from the manufacturer give a detection limit of 0·01 J-Ig/L, with an upper limit of the assay range of 25 j.lg/L.
Imprecision
Analytical performance for cTnl, myoglobin and CK-MB mass was assessed over a l-month period using a three-level quality control (QC) material supplied by the manufacturer, as there was no other suitable QC. Sequential runs were performed on a daily basis using a prerelease reagent lot for cTnI. In order to validate further analytical performance for cTnI, a second study was performed over I month as before, with sequential runs performed using a second batch of QC material and a different reagent lot.
Stability
Five patients with definite AMI had samples taken into plain Vacutainers which were allowed to clot, centrifuged, and the serum separated. The samples were assayed for cTnI and then aliquots were transferred into plain plastic tubes and stored prior to reassay for cTnI as follows: room temperature for 24 h, 4"C for 7 days, -20°C for 28 days, -70°C for 28 days. In addition, aliquots were subjected to five freezethaw cycles, with reassay between each cycle on a daily basis over a 5-day period.
Data recording
Data were recorded prospectively on all patients using a structured proforma. Patients were initially admitted and managed by the receiving physicians. The cardiac team then reviewed them on a daily basis at 0900. Patients referred for invasive investigation underwent coronary angiography at the decision of the cardiologists. The cardiologists, independent of the referring physician, decided the need for and timing of revascularization. Follow-up investigations were performed as clinically appropriate to obtain a final diagnosis.
Follow-up All patients were followed to the end of the inpatient episode by case note evaluation. Subsequent follow-up for survival, readmissions and mortality was performed using the hospital information system and by examination of hospital records. This was checked at 6 months by a follow-up letter to all patients and to the patient's GP to confirm survival status and to screen for admission to other hospitals. Daycase admissions for cardiac catheterization were not considered as acute admissions for the analysis. Survival status and cause of death were established for all patients. Cause of death was classified according to American Heart Association criteria.
Diagnostic categorization
Final diagnostic categorization on hospital discharge was made using standard WHO criteria" but incorporating cTnT measurement to confer absolute cardiospecificity. Patients were deemed to have had AMI if the elevation of CK was accompanied by elevation of cTnT. Initial classification was performed using peak CK plus cTnT (Tables 2 and 3 , WHO diagnosis using CK), and the data were then reanalysed with diagnosis utilizing peak CK-MB mass measurement instead ofCK (Tables 2 and 3 , WHO diagnosis using CK-MB) to assess the impact of the use of a more sensitive conventional diagnostic marker. Finally, all available data were reviewed, including serial CK measurements, and patients recategorized using peak CK, peak CK-MB, () CK4 plus cTnT results and the results of cardiac imaging, and a review diagnosis assigned (Tables 2 and 3 , review diagnosis). Further details of this categorization are given below.
Acute myocardial infarction was diagnosed when there were either new Q waves or I=Oh cTnl 0·827 (0'771-Q'882) 0·842 (0·788·-0'895) 0·862 (0'812--0,911) CK-MB 0·868 (0,820-0,916) 0·895 (0,852--0,937) 0·896 (0·855··0·937) Myoglobin 0·813 (0,755--0,871) 0·824 (0'767-0'880)
1=4h cTnl 0·945 (0'915-0·976) 0·958 (0,993--0,983) 0·965 (0,942--0,987) CK-MB 0·964 (0,937--0,990) 0·995 (0,990-1,000) 0·987 (0,974-0,999) Myoglobin 0·881 (0,832--0,930) 0·903 (0'859--0,947) 0·904 (0'863--0,945) 1= 12h cTnT 0·952 (0,924-0,979) 0·958 (0,931--0,984) 0·963 (0,939--0·987) cTnI 0·956 (0,930-0,982) t=Oh cTnI 0·814 (0,751-0,877) 0·818 (0,756-0,880) 0·840 (0,782-0'899) CK·MB 0·864(0,811-0,917) 0·875 (0,825-0,926) 0·883 (0,834-0'931) Myoglobin 0·819 (0,756-0,882) 0·833 (0,773-0,893) 0·817 (0,754-0'880) t=4h cTnI 0·939 (0,904-0,974) 0·956(0,928-0,984) 0·960 (0,934-0,987) CK-MB 0·966 (0,938-0,993) 0·995 (0'988-1'000) 0·986 (0,97 \-1'000) Myoglobin 0·900 (0,851-0,949) 0'921 (0'879-0,964) 0·918 (0,878-0'958) Non-ischaemic chest pain (NICP) was diagnosed when follow-up investigations allowed coronary artery disease to be excluded, or a definite source of non-cardiac chest pain could be identified.
Outcome measures
Readmission rates with AMI or unstable angina and rate of revascularization during follow-up were determined. Mortality was assessed as CCU deaths (deaths during CCU admission), inpatient deaths (patients dying during the period from admission to CCU to hospital discharge or death), and 6-month mortality (number of deaths from CCU admission to 6month follow-up).
Data handling and statistical methods All statistical analysis was performed using the ANALYSE-IT add-in for Excel (Microsoft Corporation). Non-parametric statistics were used throughout. Baseline demographics were expressed as medians and range, with UQs and LQs where appropriate. Differences in the baseline demographics and outcome measures between groups were tested by Mann-Whitney V-tests, Fisher's exact probability tests or nonparametric i statistics, as appropriate. Evaluation of diagnostic tests was by the construction of receiver-operating characteristic (ROC) curves, using AMI as the dichotomous variable.
RESULTS
Imprecision
Inter-assay CVs for CK-MB were~7·6% in the range 3·6-73· I /lg(L, and for myoglobin~7·9% in the range 54-309·9 J.lg(L, and were thus higher than those quoted by the manufacturer. Interassay CVs for cTnI were~4'1 % over the range 2·3-15·2/lg(L, and CV for one QC was 5·9% at 39·3 j.tg(L.
Sample stability
There was no evidence of instability of cTnI under a range of storage conditions. In particular, storage at -20 DC, accompanied by multiple freeze-thaw cycles, had no significant effect on measured concentrations (see Table I ).
Specificity in the non-cardiac population CK was elevated in 84(88 samples from the Marine Commandos, as expected (median 609U(L, range 72-1485, LQ 411 U(L, UQ 824 U(L). Measurement of cTnI in these samples showed that, as expected from previous studies, cTnI was undetectable in the majority of samples (72(88). There was a value in the range 0·0 I-{)·I Jlg(L in 10 subjects. Six of 88 Marine Commandos had values exceeding 0·15 Jlg(L (respectively, 0·16, 0·2, 0·26, 0·27, 0·32 and 0·4 Jlg(L). In 4(6 cases this was accompanied by a small elevation of cTnT (case I, cTnI 0·2 Jlg(L, cTnT 0·013 Jlg(L; case 2, cTnI 0·26Jlg(L, cTnT 0·017Jlg(L; case 3, cTnI 0·27Jlg(L,cTnT 0·031Jlg( L; case 4, cTnI 0·32J1g(L, cTnT 0·112J1g(L). In two cases there was lack of agreement between the cTnI and cTnT results (case I, cTnI 0·16J1g( L, cTnT < 0·01 Jlg(L; case 2, cTnI 0·4 Jlg(L, cTnT < 0·1 Jlg(L).
Diagnostic efficiency in patients with suspected ACS
On discharge there were 153 patients with AMI, 107 patients with VA and 19 with NICP. Diagnostic efficiency was examined using three different diagnostic classifications and by including and excluding patients with symptom duration > 12h. This was undertaken to examine the robustness of the tests by studying how shifting the classification scheme and the underlying population would affect test performance. The review diagnosis incorporated the use of 1J values and cardiac imaging, and so was more sensitive in detecting smaller degrees of myocardial damage. The net result of this reclassification was progressively to increase the number of patients diagnosed as having AMI from 153 (WHO diagnosis using CK-CK > 28 x VRL) to 154 (WHO diagnosis using CK-MB-eK-MB> 2 x URL) to 175 (review diagnosis, CK or CK-MB > 2 x URL, or change in CK by~20% or evidence from cardiac imaging).
Measurement of CK-MB on admission gave the best performance judged by area under the curve (AVC) of the ROC curves when all patients were included in the analysis ( 3). This AUC failed to reach significance compared to the other markers when CK was used for diagnosis, but achieved statistical significance when CK-MB was used as the diagnostic reference standard, as might be anticipated. This indicates the problem in test evaluation where a new test, which theoretically has a better performance, is compared with a potentially flawed 'gold standard'. When a more robust definition was used including all available data, including imaging, in the review diagnosis, CK-MB remained statistically significantly better than myoglobin but not c'Tnl, Reanalysis of the AVC data for the O-h time point, excluding all patients with symptom duration of more than 12h (Table 4 ), showed no significant differences between CK-MB, cTnI and myoglobin, irrespective of the diagnostic classification used. At 4 h from admission the area under the ROC curve was greatest for CK-MB. Clinical performance was equivalent to cTnI for all diagnostic classifications, irrespective of whether patients with symptoms of more than 12h duration were included or excluded from the analysis. Both CK-MB and cTnI were significantly better than myoglobin at 4 h from admission when all patients were included in the analysis, irrespective of final diagnostic classification. However, when patients with symptom duration of more than 12h were excluded, only CK-MB remained statistically significantly superior to myoglobin. At 12h from admission the diagnostic performances of CK-MB mass, cTnT and cTnI were indistinguishable and all superior to myoglobin, no matter which criteria were used for final diagnosis. ROC curves using the review diagnosis are shown in Fig. I for the individual time points.
Event rate in patients with unstable angina
In order to allow comparison with other previous studies, outcome was compared using a diagnosis based on WHO criteria. Patients were classified using both CK and CK-MB as the biochemical diagnostic criteria. In both cases, values exceeding twice the URL were considered as diagnostic for AMI. A total of 97 cases of UA were studied (all with Braunwald II1B UA), median age 66.5 years (range 27·4-86·7, LQ 57,4, UQ 76'6). There were prodromal symptoms preceding the acute episode that required admission in 34·5% of patients. Median time of onset of first symptoms to the time of initial blood sample (t = 0 h) was 5 h (range G-793, LQ 1'7, VQ 22). Median time from onset of the episode of acute cardiac symptoms causing admission to the time of initial blood sample (t=Oh) was 2·7h (range 0-129, LQ 0·8, UQ 5,5). The combined end-point of cardiac death, readmission with AMI or readmission with unstable angina (major adverse cardiac event, MACE) was examined for both WHO diagnostic categorizations at increasing diagnostic discriminants for cTnl, using increments of 0·05 J1.g/L and for the two quoted discriminants for cTnT of 0·1 J1.g/L and 0·21Ig/L. Both cTnl and cTnT predicted outcome equally, with maximal P value for both cTnl and cTnT at a discriminant value of 0·1 J1.g/L when either CK or CK-MB was used to exclude AMI. At a discriminant value of 0·2 J1.g/L, neither cTnT nor cTnI predicted outcome (Table 4 ).
DISCUSSION
The cTnI assay performed slightly better than the manufacturer's specification, with in-use assay CYs being lower than those stated in the product literature. The CYs for CK-MB and myoglobin were higher than those stated in the product literature. The CY for CK-MB mass was less than the 9·2% recommended analytical goal for imprecision.f The cTnI epitopes selected for the ACS:180 assay are reported to be stable, and we found no significant loss of immunogenicity under a range of sample storage conditions in use in the laboratory, including multiple freeze-thaw cycles. Following AMI, cTnl is released as a troponin C-cTnl complex.P which is subject to proteolysis and degradation. The Nand C regions are particularly vulnerable. Fragments located between residues 30 and liD have shown higher stability." Assays recognizing the N but not the C terminal of cTnI do not detect degradation of cTnI in samples stored at 37°c. 25 The antibody pair selected for the ACS:180 assay is directed at the N-terminal region residues 27-39 and residues 7(}-87 (Bayer Corporation, personal communication), and hence a stable region of the molecule. Our findings on sample stability are consistent with the previously reported data. This means that the assay is suitable for routine and research applications.
The pattern observed for the diagnostic performance of myoglobin, cTnl and CK-MB was consistent with the known kinetics of release of these markers." Using accepted, but different, diagnostic criteria had little effect on test efficiencies as judged by the areas under the ROC curves, with the exception of CK-MB mass on admission. It is considered that cTnI and CK-MB rise at the same time. The finding that CK-MB was superior to cTnI on admission suggests that CK-MB release is earlier than cTnl release. When considering which marker should be used as an early (short time window) marker CK·MB would seem to be a better choice for the CCU population. Here, the optimal combination of markers would therefore be CK-MB (as a rate of change or ;5 value)" plus a cardiac troponin. The use of myoglobin as an early marker is not supported by our data. The equivalent early sensitivity of myoglobin, cTnI and CK-MB was in this study due to a combination of factors. First, the median duration of symptoms was 3 h; second, there is likely to be a difference between patients admitted to the CCU and those admitted to the emergency department (ED). There is inevitably a delay in patients being transferred from the ED to a CCU. The use of an earlier and more frequent sampling regimen would be expected to show an early diagnostic superiority of myoglobin over CK-MB and cTnI.
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The optimal diagnostic cut-off for AMI determined from the ROC curve for cTnI was found to be 1·5 jlgjL using WHO criteria based on CK-MB mass, which is identical to that quoted by the manufacturer. When the review diagnosis was used, the optimal diagnostic cutoff was 1·0 jlgjL. The outcome data showed that a diagnostic cut-off of 0·1 jlgjL gave optimal separation between groups with the greatest P value and corresponded to 100% sensitivity when using the review diagnosis. The ability of cTnI to predict outcome was identical to that of cTnT. In this study, a cTnT value of 0'2jlgjL was not statistically significant as an indicator of an adverse prognosis, although we have previously found this to be the case. II This may be due to a smaller sample size.
The concentration of cTnI in the circulation of normal healthy individuals is likely to be undetectable in the majority of commercially available cTnI assays. In such subjects, the 97·5th centile of the ACS:180 assay is reported as < 0·1 jlgjL by the manufacturer. The six values exceeding 0·15 jlg/L seen in the Marine Commandos may represent true myocardial stress. In four of these cases we found a small elevation of cTnT. It has been reported that elevations of cTnT and cTnI can occur in extreme endurance marathons and are accompanied by reversible cardiac wall motion abnormalities."
This study indicates the problems in choosing a diagnostic cut-off for cardiac troponin measurement. When diagnosis is based on conventional criteria, an arbitrarily high value will be selected. Cardiac troponin measurement identifies patients without 'traditional' AMI who are at high risk of subsequent cardiac events. The diagnostic criteria influence the apparent specificity of the test. Although cardiac troponin measurements are 100% specific for cardiac damage and prognosis. specificity is less than 100% when judged against conventional diagnostic criteria. Recent discussions have reflected this in the suggestion that there are two cut-offs, one to reflect AMI, the other the presence of smaller degrees of myocardial damage. 28 • 29 This is often referred to as 'minor' myocardial injury. This is analogous to the designation of Q-wave AMI (AMI with characteristic ECG change) and non-Q AMI (biochemically detectable damage without characteristic ECG changes). It is notable that patients with either non-Q AMI or detectable cardiac troponin (cTn) are at higher risk than those with conventional Q-wave AMI. Both diagnoses represent the gradation of ischaemic heart disease (lHD) encountered in routine clinical practice. The degree of both cTnT and cTnI elevation can be correlated to the degree of risk. 12 • 14 A more pragmatic and clinically suitable classification would be into those patients with ECG change (S-T segment elevation or new Q waves), those without definitive ECG change but troponin elevation above normal, and those without ECG change or troponin elevation. This reflects current clinical practice and suggested management pathways." The paradox generated by two cutoff values has recently been addressed by the redefinition of AMI by the European Society of Cardiology and American College of Cardiology." This utilizes elevation of cTnT or cTnI above the 99th centile of an appropriate reference population in the presence of clinical or ECG features suggesting IHD.
In conclusion, the ACS:180 cTnI assay provides a useful addition to the laboratory repertoire for differential diagnosis of patients admitted with suspected ACS. Routine measurement at 12h allows both reliable diagnosis of AMI and prognostic risk stratification, equivalent to that of cTnT in this study. There have been five studies showing that cTnI measurement is prognostic in patients admitted with suspected ACS without AMI, two using the Stratus (Dade-Behnngj'<" and two the Opus system (Dade-Behringj.P'P and more recently using the Bayer Immuno I, ACS:180 and Dimension RxI.33 None of these is a single-site study with unselected sequential admissions in routine clinical practice. Subjects were either selected or highly screened as part of a clinical trial population. This is the first single-site study to show that cTnI measurement on the ACS: 180 in routine clinical samples can be used to predict risk of subsequent cardiac events. 
